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The frontotemporal degenerations (FTD) are, as a
group, considered as orphan diseases. A variety of
clinical syndromes are encompassed by FTD, includ-
ing behavioral variant FTD (bvFTD), and semantic
and nonfluent/agrammatic variants of primary pro-
gressive aphasia (PPA). Motor neuron disease or
amyotrophic lateral sclerosis (ALS) may co-occur in
small percentages of sporadic cases, and within fami-
lies with or without FTD.
Very recently, hexanucleotide repeat expansions in
the chromosome 9 open reading frame 72 (C9ORF72)
have been indentified in families with FTD with or
without ALS.1,2 This is a notable discovery in neurode-
generative disease research of FTD over the last 14
years, along with the identification of microtubule-
associated protein tau (MAPT) mutations, progranulin
(PGRN) gene mutations, and the discovery of the
TDP-43 protein as major component of ubiquitin-
positive inclusions in FTD and ALS. The presence of
the latter inclusions in both FTD and ALS has already
lent strong support to the hypothesis that both FTD
and ALS are part of a disease continuum, uniting FTD
and ALS researchers in their goals.
The discovery of the C9ORF72 repeat expan-
sion has extraordinary importance for clinical
practice in neurodegenerative diseases. This is due
in part to its very high frequency, varying between
10% and 30% in familial FTD, and 20%–50% of
familial ALS, and its broad range of clinical mani-
festations, including an anterograde amnestic de-
mentia easily mislabeled as Alzheimer disease (AD)
dementia, and its apparent occurrence in sporadic
cases. These and other aspects of C9ORF72 expan-
sion repeats are emphasized in 2 studies published
in this issue of Neurology®.3,4
There is considerable variation in age at onset and
clinical presentation among and within families with
C9ORF72 repeat expansions.3–5 For cohorts of pa-
tients with pure ALS, a younger onset age, comorbid
FTD, and apathy or dysexecutive behavior are more
common in carriers with expanded repeats.6 Motor
neuron disease occurs in approximately 20%–40%
of FTD cases with expanded repeats. The behavioral
variant, predominantly with apathy and loss of initia-
tive, is the most common clinical manifestation of
FTD in the studies of Sha et al.4 and Dobson-Stone
et al.3, as well as in other series. Both of these studies
also report the occurrence of psychotic symptoms.
Delusions, often with bizarre content, are more com-
mon than hallucinations, and sometimes lead to an
initial psychiatric diagnosis.7 The idea that psychosis
may be a clinical marker even in cases with a negative
family history seems to be somewhat premature, as
hallucinations or hallucinosis are reported much less
frequently in other studies.8,9
PPA may occur as the presenting clinical manifes-
tation of C9ORF72 repeat expansion,7–9 but was not
encountered in the studies of Dobson-Stone et al.3
and Sha et al.4 Although the small sample may ex-
plain the absence of PPA size in the first,3 the second
study should have been large enough to detect such
cases.4 Also a few cases of semantic variant PPA,
rarely associated with a family history, have been re-
ported.7,8 Parkinsonism and akinetic-rigid syn-
dromes without resting tremor frequently occur, but
are rarely the dominant presentations in patients
with C9ORF72 repeat expansions.9,10 Some cases in
Dobson-Stone et al. have the clinical diagnosis of AD
dementia, and this merits special attention as it has
important implications for clinical practice. The di-
agnosis AD dementia, also reported in other series,
can be partly ascribed to the frequent occurrence of
impaired episodic memory found in carriers with re-
peat expansions.9,11 Despite the clinical diagnosis of
AD, most of these actually were pathologically
proven cases of amnestic FTD.9,11 In the future, an-
terograde amnestic dementia patients with a strong
family history but amyloid imaging or CSF not diag-
nostic of AD could be considered candidates for
screening for C9ORF72 expansions.
Another possible distinctive feature is the pattern
of cerebral atrophy on MRI in patients with
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C9ORF72 repeat expansions. Sha et al. reported
more parietal and bilateral thalamic atrophy in pa-
tients with FTD with expansions compared to those
without. Apart from frontal, anterior temporal, and
parietal atrophy, cerebellar atrophy and changes in
diffusivity and fractional anisotropy in thalamic radi-
ations have been reported.9,10 However, the value of
these distinct anatomic profiles must be interpreted
cautiously in these small studies, and should be con-
firmed in larger studies. Finally, the presence of p62-
positive, TDP-43 negative inclusions in cerebellar
granular cells, and extensive ubiquilin pathology in
the hippocampal molecular layer and CA regions,
may neuropathologically differentiate, although not
completely, FTD and ALS cases with and without
repeat expansions.7,12,13
Every patient with FTD or ALS carrying the
GGGGCC repeat expansion has proven to share the
Finnish founder risk haplotype, or at least a part.5 As
apparently sporadic cases also carry the risk allele,
this suggests that these cases are in fact cryptically
familial cases. Incomplete penetrance is sometimes
observed in families with FTD/ALS,8 and may partly
explain the occurrence of these sporadic cases. The
study of Dobson-Stone et al. reports homozygosity
of the “non”-risk G allele at the rs3849942 locus in a
single patient carrying the repeat expansion. The au-
thors suggest that the presence of this nonrisk allele
supports the hypothesis that the expansion has oc-
curred on multiple occasions. However, as not all
patients in other studies carry the full haplotype, the
authors should have tested neighboring markers be-
fore affirming this conclusion.
Genetic counseling and genetic testing for
C9ORF72 in apparently sporadic cases is an impor-
tant clinical issue and should be carefully considered
as tests for the repeat expansion become increasingly
available. The high frequency of expanded repeats
(14%) in sporadic FTD in the study of Dobson et al.
may be due to some unrecognized recruitment bias
in this small sample size, as larger studies have re-
ported 5% or less. As incomplete penetrance occurs,
detailed information on second- and third-degree
relatives may contribute to decision-making of ge-
netic testing in apparently sporadic cases. It would be
interesting to follow-up families with apparently spo-
radic cases to examine whether they remain truly
sporadic or other relatives become affected. Byrne et
al.14 believed that genetic testing should be restricted
to patients with ALS with a family history for ALS or
FTD or cognitive/behavioral impairment, while Ma-
jounie et al. believed that testing should be consid-
ered in every patient as a technique for accurate
diagnosis.5,14 Bearing in mind the huge implications
for offspring, caution should also be exercised in the
interpretation of C9ORF72 expansion repeat testing
in sporadic cases. Repeat expansions are occasionally
found in apparent controls, and it is difficult to know
whether these individuals will eventually manifest
clinical features of ALS or FTD. Finally, the exact
cutoff indicating a pathologic repeat expansion is still
unknown. From a biological perspective, the discov-
ery of hexanucleotide repeat expansions brings FTD
and ALS into the same sphere of research as other
repeat expansions, like dystrophia myotonia, spino-
cerebellar ataxias, fragile X syndrome/FXTAS, and
Huntington disease. The location of the GGGGCC
repeat in a noncoding region, and the finding of nu-
clear RNA foci, suggest a toxic effect of mutant RNA
itself. However, the presence of RNA foci could not
be confirmed in another recent study,8 and therefore
it awaits final interpretation. Future work with trans-
genic mice and cellular models will hopefully eluci-
date the pathogenic mechanisms.
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